(Press-News.org) ANN ARBOR, Mich. — When Medicare policy changes led to reductions in reimbursement for hormonal treatment of prostate cancer, there was a sharp decline in its use among patients not likely to benefit from the treatment. But among patients for whom the therapy is clearly beneficial, doctors continued to prescribe it at the same rate, according to a new study.
This finding suggests that financial reform of health care can reduce unnecessary care without impacting care to those patients most likely to benefit from a treatment.
"We found that physicians respond to reimbursement, but they respond in a way that appears to be beneficial to the patient. They don't tend to cut out necessary care, but they tend to cut out unnecessary or inappropriate care. This suggests cutting reimbursements in the right context can help reduce unnecessary care," says lead study author Vahakn B. Shahinian, M.D., M.S., assistant professor of internal medicine at the University of Michigan Medical School and a member of the U-M Comprehensive Cancer Center.
Results of the study appear Nov. 4 in the New England Journal of Medicine.
The researchers looked at use of androgen deprivation therapy, a common type of treatment for prostate cancer that involves blocking the male hormone testosterone through a regular injection. Clinical trials have shown clear benefit for men with high-risk tumors who receive this treatment along with radiation therapy. But the benefit is less clear when androgen deprivation therapy is used by itself in lower risk tumors.
Through the 1990s, Medicare reimbursement for this therapy was set at 95 percent of the average wholesale price of the drug. The average practice got the drug for 82 percent of wholesale, which allowed for large profits by many practices. Use of androgen deprivation therapy grew until half-million men were receiving it at its peak, with more than $1 billion in Medicare expenditures.
The Medicare Modernization Act of 2003 changed policies for reimbursement of injected medications, including hormonal therapy, eventually setting it at 106 percent of the average sale price by 2005. This number was more precise than the wholesale price, as it was based on actual sales transactions reported by the pharmaceutical companies, leaving less room for profit.
Shahinian and his colleagues looked at data from 54,925 men treated for prostate cancer from 2003 to 2005, using the Surveillance, Epidemiology and End Results-Medicare database, a large population-based registry.
"SEER-Medicare has all the detailed cancer and treatment data we needed to categorize these patients, and it gave us a very good picture of the response to this change in Medicare reimbursement," said study author Yong-Fang Kuo, an associate professor at the University of Texas Medical Branch at Galveston.
Scott M. Gilbert, M.D., M.S., assistant professor of urology at the University of Florida College of Medicine, was also a co-author.
Patients were separated into three categories for androgen deprivation therapy based on the characteristics of their disease and the other treatment they received: appropriate use, potentially inappropriate use and discretionary.
Over the course of the Medicare reimbursement cuts, use of androgen deprivation therapy stayed steady for patients in the appropriate use category. Inappropriate use, however, dropped from 39 percent at the end of 2003 to 22 percent by the end of 2005. The discretionary group also declined, but more moderately.
In that time, reimbursements for ADT fell from $356 per dose in 2003 under the initial reimbursement to $176 per dose in 2005 under the revised reimbursement.
"There's a growing realization that these treatments might have more side effects than we first realized," Shahinian says. "Some of the patients who had been receiving androgen deprivation therapy would tend to do well without any treatment, and a lot of older patients die of causes other than their prostate cancer. It's inappropriate to treat these men when there is limited likelihood of benefit, no positive proof of benefit and increasing threat of side effects."
Shahinian notes that during this same time period, more studies were uncovering side effects to this treatment, which may also have influenced use of this treatment.
"Androgen deprivation therapy remains a life-saving treatment for a certain subset of patients, and in our study, those patients continued to be prescribed this treatment. Financial incentives are most likely to impact physician behavior when there's a gray zone in terms of benefit, not when there's clear evidence of life-saving benefit," Shahinian says.
###
Prostate cancer statistics: 217,730 Americans will be diagnosed with prostate cancer this year and 32,050 will die from the disease, according to the American Cancer Society
Funding: American Cancer Society
Disclosure: Shahinian is a paid consultant for Amgen
Reference: New England Journal of Medicine, Vol. 363, No. 19, Nov. 4, 2010
END
Flexible smart materials that can manipulate light to shield objects from view have been much-theorised but now researchers in Scotland have made a practical breakthrough that brings the possibility of an invisibility cardigan – or any other item of invisibility clothing - one step closer.
Two challenges to the creation of smart flexible materials that can cloak from visible light are making meta-atoms small enough to interact with visible light, and the fabrication of metamaterials that can be detached from the hard surfaces they are developed on to be used in more ...
November 4, 2010 – The autoimmune disease type 1 diabetes (T1D), also known as juvenile diabetes, is diagnosed in approximately 70,000 children worldwide per year. Genetics is increasingly being recognized as playing a significant role in susceptibility to the disorder, but outside a handful of genes, a clear understanding of the genetic architecture that underlies T1D has remained elusive. In a study published online today in Genome Research (www.genome.org), scientists have identified a novel gene associated with diabetes in mice that is revealing new clues about genomic ...
Researchers at the Ernest Gallo Clinic and Research Center at the University of California, San Francisco, and Pfizer Inc., have determined that two new compounds may be effective in treating both alcohol and nicotine dependence at the same time.
In a paper published in the November 3, 2010 issue of Neuropsychopharmacology, the researchers showed that alcohol consumption in rodents was significantly decreased by two compounds that target neuronal nicotinic acetylcholine receptor (nAChR) subtype 34*.
nAChRs are proteins found in the brain and broader ...
Remember the Star Wars scene in which R2D2 projects a three-dimensional image of a troubled Princess Leia delivering a call for help to Luke Skywalker and his allies? What used to be science fiction is now close to becoming reality thanks to a breakthrough in 3D holographic imaging technology developed at the University of Arizona College of Optical Sciences.
A team led by optical sciences professor Nasser Peyghambarian developed a new type of holographic telepresence that allows the projection of a three-dimensional, moving image without the need for special eyewear ...
SAN FRANCISCO, CA – November 3, 2010—Scientists at the Gladstone Institute of Neurological Disease (GIND) have offered new information about the events that underlie the "spread" of Alzheimer's disease (AD) throughout the brain. The research, published in the November 4th issue of the journal Neuron, follows disease progression from a vulnerable brain region that is affected early in the disease to interconnected brain regions that are affected in later stages. The findings may contribute to design of therapeutic interventions, as targeting the brain region where AD originates ...
Many gene variants have been linked to autism, but how do these subtle changes alter the brain, and ultimately, behavior?
Using a blend of brain imaging and genetic detective work, scientists at UCLA's David Geffen School of Medicine and Semel Institute for Neuroscience and Human Behavior are the first to illustrate how genetic variants rewire the brain. Published in the Nov. 3 online edition of Science Translational Medicine, their discovery offers the crucial missing physical evidence that links altered genes to modified brain function and learning.
"This is a key ...
CAMBRIDGE, Mass. -- Humans have long taken advantage of the huge variety of medicinal compounds produced by plants. Now MIT chemists have found a new way to expand plants' pharmaceutical repertoire by genetically engineering them to produce unnatural variants of their usual products.
The researchers, led by Associate Professor Sarah O'Connor, have added bacterial genes to the periwinkle plant, enabling it to attach halogens such as chlorine or bromine to a class of compounds called alkaloids that the plant normally produces. Many alkaloids have pharmaceutical properties, ...
Brain research over the past 30 years has shown that if a part of the brain controlling movement or sensation or language is lost because of a stroke or injury, other parts of the brain can take over the lost function – often as well as the region that was lost.
New research at the University of California, Berkeley, shows that this holds true for memory and attention as well, though – at least for memory – the intact brain helps out only when needed and conducts business as usual when it's not.
These results support the hypothesis that memory is not stored in one place, ...
Researchers at the University of Arizona (UA), Tucson, have developed a holographic system that can transmit a series of 3D images in near-real-time, a precursor to holographic videoconferencing.
The system incorporates a novel, photorefractive polymer--one that can rapidly refresh holographic images and is scalable for production--coupled to a unique system for recording and transmitting 3D images of individuals and objects via Ethernet.
Lead author Pierre-Alexandre Blanche and his colleagues from the university and Nitto Denko Technical Corp. of Oceanside, Calif., ...
Stroke is the leading cause of adult disability, due to the brain's limited capacity for recovery. Physical rehabilitation is the only current treatment following a stroke, and there are no medications available to help promote neurological recovery.
Now, a new UCLA study published in the Nov. 11 issue of the journal Nature offers insights into a major limitation in the brain's ability to recover function after a stroke and identifies a promising medical therapy to help overcome this limitation.
Researchers interested in how the brain repairs itself already know ...
